(Tiper Stock Exchange) – Johnson & Johnson closed the second quarter with profits above expectations and has forecasts revised upwards for the current year.
The US pharmaceutical giant, which is bolstering its pipeline of drugs and medical devices, reported a Adjusted diluted EPS of $2.80 (+8.1%), 18 cents higher than expectations (2.62 USD). The revenue rose 6.3% to 25.53 billion dollars and resonates above the expected 24.67 billion.
J&J forecasts in 2023 to generate a earnings per share of $10.60-10.70against the consensus of 10.65 USD, and a turnover of 99.3-100.3 billion dollars against a consensus of 98.96 billion.